Abstract
FRI0134 Is there any difference in ra patients for methotrexate use vs. leflunomide use as a concomitant treatment with biological and targeted synthetic dmards in turkbio registry?
Annals of the rheumatic diseases, Vol.77(Suppl 2), p.611
06/2018
DOI: 10.1136/annrheumdis-2018-eular.5662
Abstract
BackgroundTURKBIO registry is the Turkish version of Danish DANBIO rheumatologic database which has been established in 2011. Demographics and previous or current treatment with conventional (csDMARD) and targeted synthetic (tsDMARD), and biological DMARDs (bDMARDs) were collected.ObjectivesWe aimed to investigate the efficacy and safety status of methotrexate (MTX) vs. leflunomide (LEF) use as a concomitant treatment with bDMARDs and tsDMARD in this registry.MethodsFrequencies of achievement of remission or remission +low disease activity (LDA) at the 6th month of bDMARD or tsDMARD treatment were compared between patients who were on these medications with MTX vs. LEF as a concomitant treatment. Drug survival and switch rates of bDMARDs and tsDMARD treatments either with MTX or LEF were compared. The adverse effects with MTX and LEF concomitant use were evaluated as well.ResultsThe study included 725 bDMARD or tsDMARD receiving RA patients from 8 participating centres of the TURKBIO registry. Of these patients, 462 (63.7%) were receiving concomitant MTX and 263 (36.3%) LEF. Demographic findings are given in the table 1. Achievement of remission and remission +LDA at the 6th month of bDMARD or tsDMARD initiation was similar in concomitant MTX vs LEF groups (51.4% vs. 53%, p=0.683). When each bDMARD and tsDMARD was evaluated separately, achievement of remission were again similar in MTX and LEF concomitant users (TNFi: 53% vs. 54%; ABA: 50% vs. 59%; RTX: 53% vs. 61%; TCZ: 42% vs. 35%; p>0.05 for all). For TOFA, although remission +LDA rate was numerically higher in MTX concomitant group than LEF group (42% vs. 21%), the difference was not statistically significant due to the smaller sample size of TOFA (n=33). The results were similar for all DMARD groups when remission was evaluated alone. Drug survival (17±12 vs. 16±11 months, p>0.05) and drug discontinuation (42,2 vs 38, p>0.05) rates of bDMARDs or tsDMARD were also not different in MTX vs. LEF concomitant users. Adverse effects rate (19.5% vs 20.5%, p>0.05) were similar between MTX vs. LEF concomitant users as well.Abstract FRI0134 – Table 1Demographic findings of patients.ConclusionsAchievement of remission or remission +LDA was not different with the concomitant use of MTX vs. LEF with any bDMARD or tsDMARD treatment in RA patients with a similar safety profile. LEF might be an alternative as a concomitant DMARD in MTX-intolerant RA patients initiating bDMARDs or tsDMARD.Disclosure of InterestNone declared
Details
- Title: Subtitle
- FRI0134 Is there any difference in ra patients for methotrexate use vs. leflunomide use as a concomitant treatment with biological and targeted synthetic dmards in turkbio registry?
- Creators
- N. Inanc - Marmara UniversityG. Ozen - Private Practice,. , Izmir, TurkeyY. Yalcinkaya - Private Practice,. , Izmir, TurkeyE. Dalkilic - Private Practice,. , Izmir, TurkeyS.S. Koca - Fırat UniversityG. Can - Dokuz Eylül UniversityA. Karataş - Fırat UniversityY. Pehlivan - Bursa Uludağ Üni̇versi̇tesi̇A. Yazıcı - Kocaeli ÜniversitesiA. Cefle - Kocaeli ÜniversitesiA. Tufan - Gazi UniversityS. Akar - Izmir Kâtip Çelebi UniversityS. Senel - Erciyes UniversityB. Oz - Fırat UniversityN. Akkoc - Private Practice,. , Izmir, TurkeyF. Onen - Dokuz Eylül University
- Resource Type
- Abstract
- Publication Details
- Annals of the rheumatic diseases, Vol.77(Suppl 2), p.611
- Publisher
- BMJ PUBLISHING GROUP; LONDON
- DOI
- 10.1136/annrheumdis-2018-eular.5662
- ISSN
- 0003-4967
- eISSN
- 1468-2060
- Language
- English
- Date published
- 06/2018
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984702768802771
Metrics
1 Record Views